Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ad4-EnvC150

Vaccine (Adenoviral vector) · Immune activation, directed at HIV clade C Env protein (gp150 1086.C) · developed by Emergent BioSolutions

Phase 1 Most advanced trial (none active)

EBS Developer

1 Registered trials

What is Ad4-EnvC150?

Ad4-EnvC150 is a live replication-competent adenovirus type-4 vector vaccine encoding an HIV clade C envelope protein (gp150 1086.C), delivered orally via enteric-coated capsules. It is studied as an HIV vaccine candidate.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Targets: HIV clade C Env protein (gp150 1086.C) (antigen)
Mechanism: Immune activation, directed at HIV clade C Env protein (gp150 1086.C)
Therapy area: Infectious disease
Developer: Emergent BioSolutions (EBS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02771730	Phase 1	Healthy Volunteer	Terminated	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteerHIV Vaccine

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

ClinicalTrials.gov NCT02771730

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Ad4-EnvC150

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z